EFSA okays GM bacteria as feed supplementFrench Ajinomoto Eurolysine SAS, part of the world leading producer of amino acids by fermentation, has received a positive safety assessment from the European Food Safety Authority (EFSA) for use of … more ➔
CAR-T: Novartis prices CTL019 at US$475,00...Swiss Novartis AG has received US market authorisation for its first-in-class CAR-T cell therapy Kymriah (tisagenlecleucel-T). As severe cytokine storms seemed to be generally linked to CAR-T therapies … more ➔
FDA approves Boehringers biosimilar adal... The US Food and Drug Administration has granted US market authorisation to Boehringer Ingelheims biosimilar anti-TNFa-antibody adalimumab. more ➔
Apeiron bags €25m from EIB Supported by the European Fund for Strategic Investments (EFSI), the European Investment Bank (EIB) has granted a €25m loan to the Austrian pediatric cancer specialist Apeiron Biologics AG to … more ➔
Implementation of EU Unitary Patent Court... In mid-June, the German Federal Constitutional Court asked the German President not to sign legislation designed to implement the EU Unified Patent Court (UPC, EU Agreement 16351/12) and Unitary … more ➔
Daratumumab meets endpoint as first-line m...Danish Genmab A/S anti-CD38 antibody daratumumab has met the endpoint of progression-free survival in an interim analysis of Genmabs pivotal Phase III study aimed at receiving FDA approval as first-line … more ➔
Macrophage Pharma backed by Merck VenturesMerck Ventures has joined the Series A investor syndicate of the British immuno-oncology specialist Macrophage Pharma Ltd. more ➔
Parkinson’s: factor protects from ne... Scientists at Swedish Karolinska Institute have identified a factor that supports growth of midbrain dopaminergic (mDA) neurons, the nerve cells that degenerate during of Parkinsons disease. more ➔
Topas Therapeutics lands option deal with...Evotec’s immunology spin-out Topas Therapeutics has inked a multi-year R&D collaboration with pharma major Eli Lilly. The initial focus of research, which will be financed by Eli Lilly, is on identification … more ➔
Medivir licenses HCV drug MIV-802 to Chine...Medivir AB has exclusively licenced Greater China development and commercialisation rights of its preclinical candidate drug MIV-802 to Chinese drug developer Ascletis Bioscience Co. Ltd. more ➔
